For increased capacity, recovery and concentration
Merck Millipore, the life science business of Merck, has introduced single-pass tangential flow filtration (TFF) with Pellicon cassettes, an enhanced application of the company's TFF technology that allows concentration of process streams without the recirculation required in traditional TFF.
The company says this alternative application eliminates typical process constraints caused by higher volumes or concentration factors, resulting in increased capacity. It also enables continuous processing by coupling the TFF step in-line with other process steps.
The filtration system has a reduced pump size and requires less hardware, resulting in lower cost and a more compact footprint. It also allows higher concentration factors and higher product recovery.
'Tangential flow filtration is widely used by biopharmaceutical manufacturers for downstream concentration, and the industry can benefit from new ways to simplify the process,' said Daniel Stamm, Head of Global Pharma Processing. 'Merck Millipore has been collaborating with its customers on single-pass TFF process development, allowing them to meet the demands of higher titre processes without major investments in new equipment with great success.'
Merck Millipore's single-pass TFF system uses the company's proven Pellicon cassettes, which are TFF devices suitable for higher titre therapeutic antibodies as well as more demanding filtration processes that require higher operating pressures, temperatures, concentrations or caustic cleaning regimes.